ATE355829T1 - Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung - Google Patents

Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Info

Publication number
ATE355829T1
ATE355829T1 AT03760779T AT03760779T ATE355829T1 AT E355829 T1 ATE355829 T1 AT E355829T1 AT 03760779 T AT03760779 T AT 03760779T AT 03760779 T AT03760779 T AT 03760779T AT E355829 T1 ATE355829 T1 AT E355829T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
solid pharmaceutical
production
active ingredient
composition containing
Prior art date
Application number
AT03760779T
Other languages
English (en)
Inventor
Chacra-Vernet Marie-Line Abou
Noel Zakarian
Dominique Toselli
Rene Gimet
Claude Laruelle
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cll Pharma filed Critical Cll Pharma
Application granted granted Critical
Publication of ATE355829T1 publication Critical patent/ATE355829T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03760779T 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung ATE355829T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207831A FR2841138B1 (fr) 2002-06-25 2002-06-25 Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation

Publications (1)

Publication Number Publication Date
ATE355829T1 true ATE355829T1 (de) 2007-03-15

Family

ID=29720010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760779T ATE355829T1 (de) 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Country Status (12)

Country Link
US (1) US20080095838A1 (de)
EP (1) EP1521574B1 (de)
JP (1) JP2005533802A (de)
KR (1) KR20050040869A (de)
AT (1) ATE355829T1 (de)
AU (1) AU2003260621A1 (de)
CA (1) CA2490341A1 (de)
DE (1) DE60312333T2 (de)
ES (1) ES2283821T3 (de)
FR (1) FR2841138B1 (de)
WO (1) WO2004000279A1 (de)
ZA (1) ZA200500716B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2589654C (en) * 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
JP5219508B2 (ja) * 2005-05-18 2013-06-26 大日本住友製薬株式会社 ドロキシドパを含有する安定な錠剤
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2067475A4 (de) 2006-09-26 2010-12-15 Astellas Pharma Inc Tacrolimus-zubereitung mit verzögerter freisetzung
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
EP2293782B1 (de) 2008-05-06 2015-08-12 Dexcel Pharma Technologies Ltd. Stabile benzimidazolformulierung
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
CA2727488C (en) * 2008-06-13 2016-09-20 Dainippon Sumitomo Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP5953646B2 (ja) * 2009-11-24 2016-07-20 大正製薬株式会社 イブプロフェン含有固形製剤
JP5508311B2 (ja) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有4環性化合物的製劑
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
KR102584344B1 (ko) 2015-01-16 2023-09-27 추가이 세이야쿠 가부시키가이샤 병용 의약
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3668484B1 (de) * 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Neue pharmazeutische zusammensetzungen für basische oder neutrale niedermolekulare verbindungen
WO2019063478A1 (en) * 2017-09-26 2019-04-04 Capsugel Belgium Nv SUB-MICRONIC PARTICLE FORMULATIONS
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
PL3848361T3 (pl) 2018-09-04 2025-07-07 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania związku tetracyklicznego
CN114569605B (zh) * 2022-03-10 2024-08-06 沈阳药科大学 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
PT1039909E (pt) * 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
WO2000043041A1 (fr) * 1999-01-22 2000-07-27 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicamenteuses presentant une meilleure absorption orale
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption

Also Published As

Publication number Publication date
FR2841138B1 (fr) 2005-02-25
ZA200500716B (en) 2006-09-27
DE60312333T2 (de) 2007-12-20
EP1521574A1 (de) 2005-04-13
FR2841138A1 (fr) 2003-12-26
KR20050040869A (ko) 2005-05-03
DE60312333D1 (de) 2007-04-19
ES2283821T3 (es) 2007-11-01
US20080095838A1 (en) 2008-04-24
AU2003260621A1 (en) 2004-01-06
EP1521574B1 (de) 2007-03-07
WO2004000279A1 (fr) 2003-12-31
CA2490341A1 (fr) 2003-12-31
JP2005533802A (ja) 2005-11-10

Similar Documents

Publication Publication Date Title
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
WO2003090726A3 (en) Chewable soft capsule
EP1483579A4 (de) Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
SE0001899D0 (sv) New compounds
EP0693281A3 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EP1281722A4 (de) Hyaluronsäuregel, verfahren zu dessen herstellung sowie das gel enthaltendes medizinisches material
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
EP1291362A4 (de) Komplex aus folsäure und polysacchariden, dessen herstellung sowie diesen komplex als aktiven bestandteil enthaltende pharmazeutische zusammensetzung
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
WO2004032862A3 (en) Cyclodextrin-based materials, compositions and uses related thereto
DE60021749D1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
CA2391076A1 (en) Solutions containing epinastin
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
BR0211063A (pt) Sais de derivados anticonvulsivantes
SE0001916D0 (sv) Novel formulation
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties